{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Consolidation", "query": { "condition": "Lung Consolidation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 306, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Consolidation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T20:48:57.316Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Limited Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "BMS-986489", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2025-03-11", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 34, "location_summary": "Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06773910" }, { "nct_id": "NCT00034372", "title": "Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "oregovomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Unither Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 102, "start_date": "2000-09", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2007-12-18", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 12, "location_summary": "Newport Beach, California • Stanford, California • Orlando, Florida + 8 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00034372" }, { "nct_id": "NCT00003899", "title": "Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "1999-01", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003899" }, { "nct_id": "NCT00003634", "title": "Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "oregovomab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AltaRex", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 400, "start_date": "1998-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 29, "location_summary": "Berkeley, California • Los Angeles, California • Orange, California + 25 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003634" }, { "nct_id": "NCT00581776", "title": "Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-05", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00581776" }, { "nct_id": "NCT03709758", "title": "Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 50, "start_date": "2018-10-17", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 2, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709758" }, { "nct_id": "NCT00771602", "title": "Alemtuzumab + Rituximab Consolidation in CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-08", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771602" }, { "nct_id": "NCT00725283", "title": "Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukaemia, Myelocytic, Acute" ], "interventions": [ { "name": "GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2008-10-01", "completion_date": "2016-06-22", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 9, "location_summary": "Tampa, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725283" }, { "nct_id": "NCT07489066", "title": "Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Non-Small-Cell Lung", "Lung Cancer (NSCLC)", "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung (NSCLC)", "Lung Disease", "Non-Small Cell Lung Cancer", "Non-small Cell Lung Cancer, Non-squamous", "Non-small Cell Lung Cancer, Squamous" ], "interventions": [ { "name": "PF-08634404", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Regimen 1", "type": "DRUG" }, { "name": "Chemotherapy Regimen 2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-06-30", "completion_date": "2031-07-30", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 7, "location_summary": "Huntsville, Alabama • Athens, Georgia • Hinsdale, Illinois + 3 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Athens", "state": "Georgia" }, { "city": "Hinsdale", "state": "Illinois" }, { "city": "New Lenox", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07489066" }, { "nct_id": "NCT07603375", "title": "Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-09", "completion_date": "2034-02", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-13T20:48:57.316Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07603375" } ] }